Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub
https://doi.org/10.64483/jmph-97

Cardiac Amyloidosis: An Updated Review for Pharmacists, Nursing, and Radiologists.

Abdulaziz Mohammad Khtlan Alruwalil (1) , Raaed Saad Alaofy (2) , Ibrahim Freed Kuwaiti (3) , Ali Mohammed Awed Alghamdi (4) , Menawer Sayaah Menawer Alenazi (5) , Amirah Masfer Al Salem (6) , Fahad Abdullah Alharbi (7) , Atheer Omar Mohammed Alhejaili (8) , Bader Metib Alazmy (9) , Turki Ayesh Almutairi (10) , Majdi Raji Naffa Alharbi (11) , Maha Abdulhadi Jarallah Alenezi (12) , Salha Eissa Shami (13) , Sami Masaad Aljabri (14) , Saleh Hamdan Almrwani (15)

(1) Swyer General Hospital, Ministry Of Health, Saudi Arabia,
(2) Al Nakheel Health Center, Ministry Of Health, Saudi Arabia,
(3) King Fahad Hospital Medina, Ministry Of Health, Saudi Arabia,
(4) Erada Mental Health Complex Hospital, Ministry Of Health,Saudi Arabia,
(5) Al-Jabr Of The Eyes, Nose, Ear And Throat Hospital, Ministry Of Health, Saudi Arabia,
(6) Ministry Of Health, Saudi Arabia,
(7) King Saud Hospital In Unizah, Ministry Of Health, Saudi Arabia,
(8) Uhod Hospital-Nicu, Saudi Arabia,
(9) Ministry Of Health, Nafi General Hospital, Ministry Of Health, Saudi Arabia,
(10) Prince Sultan Medical Military City Riyadh, Ministry Of Health, Saudi Arabia,
(11) King Salman Medical City, Ministry Of Health, Saudi Arabia,
(12) Quba Primary Health Care Center, Ministry Of Health, Saudi Arabia,
(13) Sabya General Hospital, Ministry Of Health, Saudi Arabia,
(14) Ministry Of Health, Madinah, Saudi Arabia,
(15) Forensic Services Department, Ministry Of Health, Saudi Arabia

Abstract

Background: Cardiac amyloidosis is an infiltrative cardiomyopathy caused predominantly by misfolded immunoglobulin light chains (AL) or transthyretin (ATTR), leading to diastolic dysfunction, conduction disease, and heart failure. Early recognition remains challenging due to overlap with common conditions.
Aim: To provide an updated, practice-oriented synthesis for pharmacists, nurses, and radiologists/nuclear medicine physicians on epidemiology, pathophysiology, diagnostic pathways, and therapeutics.
Methods: Narrative review and critical integration of contemporary consensus algorithms and modality-specific evidence regarding electrocardiography, echocardiography (strain), cardiac magnetic resonance (LGE, T1/ECV), bone–avid scintigraphy (Tc-PYP with SPECT/CT), endomyocardial biopsy, genotyping, and disease-modifying therapy.
Results: Hallmark features include voltage–mass discordance, apical-sparing strain, diffuse subendocardial/transmural LGE with elevated native T1/ECV and reversed nulling order, and grade 2–3 Tc-PYP uptake (with negative monoclonal screen) confirming ATTR. Management is phenotype-specific: clone-directed therapy (e.g., Dara-CyBorD, ASCT) for AL; TTR stabilization (tafamidis) and silencers (for neuropathy) for ATTR. Across phenotypes, diuretics/MRAs anchor volume control; β-blockers and RAAS inhibitors are often poorly tolerated; anticoagulation is frequently indicated. Role-specific contributions—medication safety/access (pharmacists), surveillance and self-management support (nurses), protocolized imaging and reporting (radiology/nuclear)—shorten time-to-diagnosis and improve outcomes.
Conclusion: Implementing a structured diagnostic algorithm and phenotype-tailored therapy within an interprofessional model materially improves safety, timeliness, and quality of care in cardiac amyloidosis.
Keywords: cardiac amyloidosis; ATTR; AL amyloidosis; cardiac MRI; Tc-PYP SPECT/CT; tafamidis; daratumumab; interdisciplinary care..

1. Introduction

Amyloidosis constitutes a multisystem disorder defined by the extracellular accretion of insoluble, misfolded protein aggregates. Within the cardiovascular system—termed cardiac amyloidosis or amyloid cardiomyopathy—these fibrillar deposits infiltrate the myocardial interstitium, insinuating themselves between adjacent cardiomyocytes. The resultant architectural distortion precipitates myocyte injury diminishes ventricular compliance, and markedly augments myocardial stiffness, thereby compromising diastolic filling and global cardiac

*Corresponding author e-mail: Azoz_Lx@Hotmail.Com (Abdulaziz Mohammad Khtlan Alruwalil).
Receive Date: 12 November 2024, Revise Date: 22 December 2024, Accept Date: 31 December 2024

performance. Two aberrantly folded precursor proteins account for the vast majority of cases: monoclonal immunoglobulin light chains and transthyretin, the latter frequently designated amyloid transthyretin (ATTR), a transport protein responsible for carrying thyroxine and retinol.[1] Epidemiologically, amyloid light-chain (AL) amyloidosis represents the predominant phenotype, with an estimated annual incidence exceeding ten individuals per million, underscoring its clinical relevance despite relative rarity. By contrast, ATTR amyloidosis arises from the tissue deposition of either wild-type (nonmutant) transthyretin or its mutant variants, reflecting divergent pathobiological trajectories that converge on the same morphological endpoint of fibril accumulation within the myocardium.[2] Additional etiologic pathways for amyloid formation—beyond AL and ATTR—are recognized and elaborated in comprehensive discussions of causation (see Etiology), but they contribute a smaller proportion of cardiac involvement relative to these principal subtypes.

From a nosological perspective, cardiac amyloidosis occupies the foremost position among restrictive cardiomyopathies, accompanied by cardiac sarcoidosis and cardiac hemochromatosis as other key infiltrative exemplars. The infiltrative cardiomyopathy rubric is typified by impaired diastolic function occurring in the context of a nondilated left ventricle, a hemodynamic signature that helps differentiate these entities from dilated or hypertrophic cardiomyopathic processes.[3] Irrespective of the specific amyloid protein driving the disease cascade, myocardial involvement is the principal determinant of outcome in systemic amyloidosis and constitutes the dominant proximate cause of death across this patient population.[4] Clinically, cardiac amyloidosis may declare itself as a primary presentation—with heart failure symptoms, conduction disease, arrhythmia, angina-like chest discomfort from microvascular impairment, or syncope—or it may be uncovered incidentally during evaluation for extra-cardiac manifestations of systemic amyloid deposition, such as neuropathy, nephrotic-range proteinuria, or hepatosplenomegaly. Unfortunately, both diagnosis and initiation of disease-modifying therapy are frequently deferred by non-specific early features, overlap with more prevalent cardiovascular conditions, and limited initial suspicion, all of which contribute to clinically meaningful delays.[5] Such lagging recognition is consequential: the presence and extent of cardiac involvement convey profound prognostic weight in systemic amyloidosis, serving as the most critical predictor of survival and long-term clinical trajectory in affected individuals.[6]

Pathophysiologically, the interstitial accrual of amyloid fibrils stiffens the ventricular walls and attenuates relaxation, producing the characteristic restrictive physiology with elevated filling pressures and preserved or only modestly reduced ejection fraction until late disease. Progressive infiltration impairs longitudinal strain—often with apical sparing on advanced imaging—and can involve the conduction system, fostering atrioventricular block, atrial arrhythmias, and ventricular dysrhythmias. Macro- and microvascular compromise further limit myocardial perfusion reserve, while valvular thickening and atrial remodeling compound hemodynamic burden. These structural and functional derangements explain the common clinical picture of exertional intolerance, right-sided congestion, and refractory diuresis needs despite seemingly “normal-sized” ventricles on imaging. Given the protean manifestations and the potential for rapid decompensation, a high index of suspicion is warranted in patients with unexplained heart failure with preserved ejection fraction, discordantly increased ventricular wall thickness relative to low QRS voltages, or multisystem “red flags” suggestive of systemic amyloidosis. Although the detailed diagnostic algorithm and therapeutic landscape—ranging from clone-directed therapies in AL to transthyretin stabilization or gene-silencing strategies in ATTR—extend beyond the scope of this synopsis, timely identification remains paramount. In sum, cardiac amyloidosis is the prototypical infiltrative restrictive cardiomyopathy: it arises chiefly from AL and ATTR protein misfolding, exhibits a distinct diastolic dysfunction phenotype with nondilated ventricles, and, above all, dictates prognosis in systemic amyloidosis—facts that collectively underscore the urgency of early recognition and intervention.[1][2][3][4][5][6]

Figure-1: Cardiac Amyloidosis on Transthoracic Echocardiogram.

Etiology:

Cardiac amyloidosis arises from the extracellular accrual of a toxic, fibrillar material collectively termed amyloid—an organized aggregate of misfolded proteins intimately interwoven with matrix-associated constituents, including proteoglycans, glycosaminoglycans, collagen, and laminin. This composite substance is not merely inert debris; rather, it actively perturbs tissue architecture and biomechanics, undermining normal myocardial compliance and impairing chamber filling. The proteomic backbone of these aggregates typically originates from two principal precursors: immunoglobulin light chains and transthyretin (ATTR). In each case, conformational destabilization permits monomers or oligomers to misassemble and polymerize into insoluble fibrils that resist proteolytic clearance, culminating in progressive myocardial infiltration and dysfunction. On ultrastructural examination, amyloid fibrils are classically nonbranching, with a uniform diameter in the range of 7–10 nm. Their pervasive sequestration within the interstitium stiffens the ventricular wall and disrupts the viscoelastic properties of the myocardium, thereby compromising diastolic filling long before overt systolic failure is evident. Consistent with this pathophysiology, diastolic dysfunction generally precedes measurable systolic impairment, which tends to manifest later in the disease trajectory as infiltration advances and contractile reserve is exhausted. This temporal sequence—diastolic derangement followed by eventual systolic compromise—constitutes a defining clinical hallmark of the disorder.[7]

Multiple etiologic subtypes of cardiac amyloidosis are recognized, reflecting the biochemical identity of the precursor protein and the underlying systemic condition that drives its overproduction or misfolding. Primary amyloidosis (amyloid light-chain, AL) results from the production and deposition of monoclonal light chains generated by clonal plasma cells. These misfolded light chains assemble into amyloid fibrils that deposit widely, including in the heart, and the process is frequently associated with plasma cell dyscrasias such as multiple myeloma. In this setting, the cardiotoxicity of circulating light-chain species and the mechanical consequences of fibrillar infiltration act in concert, yielding a particularly aggressive form of cardiomyopathy. Secondary amyloidosis (amyloid A, AA) is mechanistically distinct, arising from the deposition of fragments of serum amyloid A, an acute-phase reactant whose concentration is chronically elevated in the context of protracted inflammatory states. Rheumatologic diseases, chronic infections, and other inflammatory conditions can sustain high SAA levels, favoring misfolding and systemic deposition. Although AA amyloid has a predilection for certain organs, cardiac involvement may occur and, when present, can substantially worsen clinical outcomes by superimposing restrictive physiology on the systemic disease burden [7].

ATTR amyloidosis comprises two major categories unified by the transthyretin precursor yet distinguished by its molecular provenance. In wild-type ATTR (ATTRwt), previously referred to as senile systemic amyloidosis, age-related conformational instability of native transthyretin promotes fibrillogenesis without an underlying gene mutation. ATTRwt is strongly linked to advancing age and frequently targets the heart, where it can produce a progressive restrictive cardiomyopathy with conduction disturbances and heart failure symptoms in older adults. Variant or hereditary ATTR (ATTRv), formerly termed "familial amyloidosis," is driven by pathogenic mutations in the TTR gene that destabilize the tetrameric structure, thereby enhancing the dissociation of monomers and promoting fibril formation. More than 130 TTR variants have been documented worldwide, with notable geographic and ethnic clustering. In the United States, a commonly encountered allele involves a Val122Ile substitution at residue 122, which confers a heightened risk of cardiac involvement and often presents as late-onset cardiomyopathy. The clinical expression of ATTRv is heterogeneous, spanning predominantly neurologic phenotypes, predominantly cardiac phenotypes, or mixed multisystem disease, depending on the specific mutation and modifying factors. Beyond AL, AA, and ATTR, several rarer amyloidogenic proteins can involve the myocardium. Hereditary apolipoprotein A-I and A-IV amyloidoses can lead to systemic deposition that includes cardiac tissue, though their prevalence is considerably lower than the major forms. In addition, isolated atrial amyloidosis represents a distinct entity characterized by amyloid derived from atrial natriuretic peptide, primarily localized to atrial tissue and often identified in older individuals. While typically more limited in anatomic distribution, such deposition can contribute to atrial remodeling and arrhythmogenic substrates, compounding the hemodynamic impact of coexisting cardiac pathology [7].

In sum, the etiologic landscape of cardiac amyloidosis reflects a convergence of protein misfolding biology and extracellular matrix interactions. Whether initiated by monoclonal light chains in plasma cell dyscrasias, by chronic inflammatory upregulation of serum amyloid A, or by age-related or hereditary destabilization of transthyretin, the common final pathway is deposition of rigid, nonbranching fibrils within the myocardial interstitium. This process inexorably remodels the heart toward a restrictive physiology, with diastolic dysfunction as the earliest functional signature and later systolic decline marking more advanced disease.[7] Recognition of the precursor protein and its source is therefore central to diagnosis, prognostication, and therapy, as disease-modifying strategies must be tailored to the specific amyloid type driving cardiac involvement.



Figure-2: Global Longitudinal Strain Analysis for Cardiac Amyloidosis.

Epidemiology

Cardiac amyloidosis remains an uncommon but increasingly recognized cause of myocardial disease, with its population burden differing substantially according to the underlying amyloid precursor protein. In the context of plasma cell dyscrasias, amyloid light-chain (AL) amyloidosis is a notable complication: approximately one in ten individuals with multiple myeloma develop AL amyloidosis, and among those with AL, cardiac infiltration is detected in roughly 50% to 70% of cases. These figures underscore the heart's particular vulnerability to light-chain–mediated toxicity and deposition. At the population level, the annual incidence of AL amyloidosis has been estimated at approximately 1 per 100,000 persons, reflecting both the relative rarity of the condition and the challenges inherent in timely case ascertainment, given its protean clinical manifestations and historic underrecognition. Hereditary or variant transthyretin amyloidosis (ATTRv) is marked by marked genetic heterogeneity, with more than a hundred distinct pathogenic variants described in the transthyretin gene. The epidemiologic distribution of these mutations varies by ancestry and geography, producing regional "hot spots" and population-specific risks. In the United States, for example, the Val122Ile (p.Val142Ile) substitution is of particular relevance to individuals of African ancestry. In one cohort of 14,333 African American participants, the Val122Ile allele was identified in 1.73%, emphasizing that a nontrivial fraction of this population harbors a variant associated predominantly with cardiac deposition and late-onset cardiomyopathy.[8] Such data have sharpened attention to ancestry-tailored risk stratification and have implications for screening strategies in symptomatic older adults, especially those presenting with otherwise unexplained heart failure phenotypes [8].

Wild-type transthyretin amyloidosis (ATTRwt), historically termed senile systemic amyloidosis, constitutes the most prevalent substrate for amyloid cardiomyopathy in older populations. Autopsy and contemporary clinical series converge on the observation that ATTRwt deposits are present in more than 10% of persons over the age of 60 years, and that the resulting cardiomyopathy is frequently mislabeled as heart failure with preserved ejection fraction (HFpEF) due to overlapping clinical and echocardiographic features. The clinical interface between ATTRwt and other age-associated cardiac conditions is further highlighted by the observation that at least 10% of patients with aortic stenosis harbor coexisting ATTRwt deposition, a concurrence that may modify hemodynamics, procedural risk, and postoperative recovery. Moreover, among adults older than 65 years who carry a diagnosis of HFpEF, between 10% and 15% exhibit evidence of transthyretin-derived amyloid, indicating that a meaningful subset of presumed "idiopathic" HFpEF conceals an infiltrative etiology amenable to specific diagnostic pathways and, increasingly, targeted therapies.[9] Trends in epidemiologic indicators corroborate the clinical impression that cardiac amyloidosis is being recognized with greater frequency. Over the past dozen years, population-based estimates of prevalence have nearly doubled—from approximately 8 to 17 per 100,000 person-years—mirroring improvements in disease awareness across cardiology and hematology communities, broader deployment of noninvasive diagnostic modalities, and enhanced survival that expands the pool of individuals living with diagnosed disease.[10] While ascertainment bias and evolving coding practices undoubtedly contribute to these curves, the trajectory strongly suggests that earlier paradigms grossly underestimated the true burden of disease, particularly among older adults with multimorbidity [9][10].

Taken together, the epidemiologic landscape of cardiac amyloidosis reflects intersecting biological and demographic forces: the rarity yet clinical gravity of AL amyloidosis in plasma cell disorders; the ancestry-linked distribution of ATTRv variants such as Val122Ile, which enrich risk within specific populations; and the age-driven predominance of ATTRwt in individuals entering their seventh decade and beyond. The frequent masquerade of amyloid cardiomyopathy as more common syndromes—HFpEF or degenerative valve disease—underpins historical underdiagnosis and misclassification. Contemporary data now argue for heightened diagnostic vigilance in several sentinel scenarios: older adults with HFpEF of unclear origin; patients with low-flow, low-gradient aortic stenosis or disproportionate right-sided congestion; and individuals of at-risk ancestries presenting with late-onset, conduction-system disease or unexplained increases in ventricular wall thickness. As diagnostic algorithms mature and disease-modifying therapies proliferate, continued refinement of epidemiologic estimates is anticipated. Nonetheless, current evidence already supports a strategic recalibration of clinical suspicion: while cardiac amyloidosis remains numerically rare in the general population, it is decidedly not rare within specific, readily identifiable clinical niches. Recognition of this stratified risk is critical for timely diagnosis, appropriate referral, and equitable access to interventions that can meaningfully alter the natural history of disease [8][9][10].

Pathophysiology

Amyloid-driven cardiac dysfunction arises through a convergence of structural, microvascular, electrical, and biochemical insults that progressively remodel the myocardium and its conducting and autonomic apparatus. The foundational process is direct interstitial infiltration: insoluble fibrils accumulate within the extracellular matrix of the ventricular walls, thickening the myocardium without proportional myocyte hypertrophy and thereby increasing passive stiffness. This remodeling impairs ventricular relaxation and elevates filling pressures, so diastolic dysfunction reliably precedes measurable decline in systolic pump performance. As a result, early disease is typified by symptoms and signs of impaired compliance—exertional dyspnea, edema, and elevated natriuretic peptides—despite a left ventricular ejection fraction that may initially remain within normal limits [9][10]. Microvascular involvement further amplifies myocardial dysfunction. In amyloid light-chain (AL) amyloidosis, deposition within intramural arterioles narrows luminal caliber and perturbs endothelial function. The resulting mismatch between myocardial oxygen demand and delivery produces angina pectoris in the absence of epicardial coronary stenoses and, on occasion, can precipitate bona fide myocardial infarction. This microcirculatory compromise occurs alongside interstitial infiltration, jointly limiting perfusion reserve and aggravating subendocardial ischemia during stress. In parallel, infiltration of the atrial myocardium fosters diffuse interstitial changes—fibrosis, altered conduction, and mechanical discoordination—that form a fertile substrate for atrial fibrillation. Importantly, even when sinus rhythm is maintained, atrial amyloidosis impairs reservoir and conduit function, predisposing to atrial blood stasis. Consequently, the risks of atrial thrombosis and systemic thromboembolism are elevated independent of conventional rhythm-based risk stratification [9][10]. Beyond architectural and vascular effects, AL amyloidosis imposes a distinct biochemical cardiotoxicity. Circulating light chains themselves can directly injure cardiomyocytes by provoking oxidative stress. Through the generation of reactive oxygen species, these misfolded proteins perturb mitochondrial function, destabilize cellular calcium handling, and activate maladaptive signaling cascades, culminating in myocyte apoptosis and fibrosis. Thus, in AL disease the heart is assaulted both mechanically—by extracellular fibril burden—and metabolically—by soluble factors that accelerate functional decline even before massive deposition is evident.

The molecular provenance of amyloid dictates the path from precursor to fibril. In AL amyloidosis, clonal plasma cells synthesize aberrant immunoglobulin light chains that misfold and polymerize amyloid fibrils. By contrast, in transthyretin (ATTR) amyloidosis the critical step is destabilization of the native transthyretin tetramer. With aging or in the presence of pathogenic mutations, the tetramer dissociates more readily into monomers and small oligomers that misassemble into amyloid. These intermediates and their fibrillar end products deposit within the myocardium, progressively stiffening the walls and compromising both diastolic and, with time, systolic function. Isolated atrial amyloidosis follows yet another biochemical route: here, the precursor is atrial natriuretic peptide, which undergoes conformational change and deposition primarily within atrial tissue, amplifying atrial remodeling and arrhythmogenicity [9][10]. As infiltration advances, contractile mechanics deteriorate. Thickened, noncompliant ventricles exhibit reduced longitudinal shortening and an impaired Frank–Starling response, yielding a fall in stroke volume. Initially, compensatory mechanisms may preserve ejection fraction, but progressive disruption of myocardial architecture and cumulative myocyte injury eventually erode systolic performance. This trajectory—preserved ejection fraction giving way to overt systolic impairment—mirrors the histopathologic march from patchy interstitial deposits to more confluent infiltration with replacement fibrosis. Electrical conduction is frequently compromised by amyloid involvement of specialized tissues. Deposition within the sinoatrial node slows impulse generation; infiltration of the atrioventricular node and His–Purkinje system retards impulse propagation. Clinically, this spectrum manifests sinus node dysfunction, first- through third-degree atrioventricular block, bundle branch blocks, and various intraventricular conduction delays. These abnormalities not only produce bradyarrhythmias and syncope but also degrade atrioventricular synchrony and ventricular filling, further worsening hemodynamics in an already stiff ventricle [9][10].

Autonomic nervous system involvement is a prominent feature in ATTR amyloidosis, particularly in hereditary (ATTRv) forms. Amyloid infiltration of autonomic ganglia and peripheral sympathetic and parasympathetic fibers blunts baroreflexes and impairs vascular tone. The clinical sequelae—orthostatic hypotension, lightheadedness or syncope, and gastrointestinal dysmotility—compound cardiac limitations by reducing effective preload, destabilizing blood pressure, and undermining nutritional status. In advanced cases, autonomic failure interacts with conduction disease and atrial arrhythmias to create a complex, brittle hemodynamic state that is highly sensitive to modest shifts in volume or afterload. Taken together, the pathophysiology of cardiac amyloidosis is multifactorial and self-reinforcing. Interstitial fibril deposition stiffens the myocardium; microvascular compromise limits perfusion; atrial remodeling begets arrhythmia and thrombosis; soluble toxic species, particularly in AL disease, induce oxidative myocyte injury; and infiltration of the conduction and autonomic systems destabilizes rhythm and vascular control. Although the initiating biochemistry differs among AL, ATTR, and isolated atrial forms, each converges on a common final pathway: progressive myocardial infiltration that first impairs diastolic relaxation, then diminishes systolic output, and ultimately orchestrates the clinical syndrome of restrictive cardiomyopathy with high arrhythmic and thromboembolic risk. Early recognition of these mechanistic layers is essential, as interventions that target the precursor protein, mitigate oxidative stress, or support electrical stability may meaningfully alter the trajectory of organ dysfunction [9][10].

History and Physical

Individuals with amyloidosis may come to clinical attention through overt cardiac manifestations or, alternatively, be identified incidentally while undergoing assessment for extra-cardiac disease. The historical profile frequently mirrors that of congestive heart failure, which can obscure early recognition. Patients commonly describe exertional fatigue and progressive dyspnea, often accompanied by orthopnea and paroxysmal nocturnal dyspnea that reflect impaired ventricular relaxation and elevated filling pressures. Dependent edema of the lower extremities and abdominal distension—whether from ascites or visceral congestion—are also typical. Symptoms attributable to arrhythmia are prevalent as well: patients may report episodic palpitations, chest discomfort, presyncope, or frank syncope, reflecting atrial and ventricular rhythm disturbances and conduction system involvement that are characteristic of infiltrative cardiomyopathy [11]. Beyond the cardiovascular system, a substantial subset present with musculoskeletal and peripheral nerve complaints that, in retrospect, serve as important diagnostic clues. Median neuropathy at the wrist is a classic association. Patients often note paresthesias—tingling and numbness—in the thumb, index, middle, and radial half of the ring finger, sometimes coupled with nocturnal symptoms, wrist pain, and difficulty with fine motor tasks or sustained grip, all suggestive of carpal tunnel syndrome. Degenerative changes leading to lumbar spinal stenosis may present as chronic lower back pain, neurogenic claudication, or gait limitation, which can be mistakenly attributed solely to age-related spondylosis. A length-dependent polyneuropathy is another salient feature, manifesting as distal sensory loss, burning pain, and allodynia in the feet and hands; with progression, motor involvement produces distal weakness, impaired balance, and falls. Superimposed autonomic dysfunction is common and contributes to a diverse symptom burden: chronic diarrhea or constipation, early satiety with unintentional weight loss, erectile dysfunction, and lightheadedness upon standing consistent with orthostatic hypotension. Taken together, these noncardiac manifestations often precede or accompany cardiac symptoms and should heighten suspicion for a systemic amyloid process.

The physical examination tends to corroborate the multisystem nature of disease. General inspection may reveal periorbital edema and facial puffiness, signs of intravascular volume overload and capillary leak. Jugular venous pressure is frequently elevated, sometimes with prominent v waves in the setting of tricuspid regurgitation or atrial dysfunction; peripheral findings typically include bilateral pitting pedal edema. Macroglossia—a broadened, thickened tongue that may display scalloping from dental impressions—is a distinctive feature that, when present, strongly suggests an amyloid etiology. Blood pressure assessment should include orthostatic measurements, as postural hypotension is frequent due to autonomic impairment and can substantially limit functional capacity [11]. Cardiovascular examination often discloses precordial findings consistent with restrictive physiology. A third heart sound (S3) may point to elevated filling pressures and incipient heart failure, whereas a fourth sound (S4) can signal reduced ventricular compliance; both may be soft or absent in advanced stages when atrial contraction is ineffective, especially during atrial fibrillation. Heart sounds can be distant or muffled when pericardial effusion is present, a not uncommon accompaniment of advanced infiltration. Hepatic congestion is reflected by tender hepatomegaly, and shifting dullness or a fluid wave may indicate ascites; these abdominal findings integrate with the history of abdominal distension to support right-sided failure physiology. In the extremities and musculoskeletal system, a “Popeye sign”—a bulging distal muscle belly of the biceps—may be appreciated, suggesting distal or biceps tendon rupture and hinting at underlying connective tissue fragility. Careful neurologic and orthopedic examination may elicit Tinel or Phalen signs at the wrist, distal sensory loss in a stocking-glove distribution, reduced ankle reflexes, or intrinsic hand muscle weakness, all consistent with carpal tunnel syndrome and peripheral neuropathy. In sum, the historical and physical examination profile of cardiac amyloidosis is a tapestry of heart failure–like symptoms, arrhythmia-related complaints, and systemic features rooted in neuropathic, autonomic, and musculoskeletal involvement. Clinicians should maintain a high index of suspicion when otherwise unexplained heart failure symptoms coexist with carpal tunnel syndrome, neuropathic pain or weakness, orthostatic intolerance, macroglossia, and signs of volume overload. Recognition of these patterned constellations at the bedside is central to prompting definitive evaluation and expediting disease-specific therapy.[11]

Evaluation

The 2023 American College of Cardiology Expert Consensus on Cardiac Amyloidosis underscores a structured, algorithmic approach to patients in whom this diagnosis is contemplated. Because the clinical phenotype frequently mimics more common cardiovascular syndromes, accurate identification depends on sustained vigilance and the deliberate integration of cardiac and extra-cardiac clues. Cardiologists and other frontline clinicians should be prepared to initiate a targeted workup whenever historical features, examination findings, or routine tests suggest a possible infiltrative cardiomyopathy attributable to amyloid deposition. A broad review of systems often yields sentinel hints. Symptomatically, patients may report fatigue and the cardinal manifestations of heart failure—exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, and abdominal distension from visceral congestion. Arrhythmia-related complaints are rife: palpitations, chest discomfort, lightheadedness, presyncope, or true syncope reflect conduction system infiltration and atrial or ventricular dysrhythmias. Systemic and musculoskeletal markers provide further leverage for suspicion. Bilateral carpal tunnel syndrome, spontaneous tendon rupture, lumbar spinal stenosis or chronic lumbar pain, and prior large-joint arthroplasty (eg, hip or knee) frequently accompany transthyretin amyloidosis. Neurologic involvement may manifest length-dependent peripheral neuropathy or autonomic failure presenting with erectile dysfunction, gastrointestinal dysmotility (gastroparesis, diarrhea, or constipation), orthostatic hypotension, urinary incontinence, and, in renal involvement, nephrotic-range proteinuria. Medication intolerance, especially hypotension with standard vasodilators—can be a subtle, yet informative, red flag in this setting.

Initial, noninvasive tests often reveal a characteristic pattern. The resting electrocardiogram (ECG) may show a pseudo-infarction pattern with pathologic-appearing Q waves or diffuse low limb-lead voltages that contrast sharply with the increased left ventricular (LV) wall thickness observed on imaging. Atrial fibrillation and assorted conduction disturbances are common. Transthoracic echocardiography typically demonstrates increased myocardial wall thickness, biatrial enlargement, rapid progression of diastolic dysfunction, and, frequently, small pericardial or pleural effusions. In many patients, speckle-tracking strain imaging discloses apical sparing of longitudinal strain—a signature pattern discussed below. Cardiac magnetic resonance (CMR) often reveals diffuse subendocardial or transmural late gadolinium enhancement and abnormal myocardial nulling, consistent with extensive interstitial expansion. Biomarkers add complementary evidence: persistently elevated low-level troponin I and increased N-terminal pro–B-type natriuretic peptide (NT-proBNP), out of proportion to alternative explanations, further heighten concern for infiltrative cardiomyopathy.

Once suspicion is established, the diagnostic sequence prioritizes exclusion of amyloid light-chain (AL) amyloidosis because of its distinct management and typically more aggressive natural history. Three monoclonal protein studies should be obtained: a serum κ/λ free light chain assay, serum immunofixation electrophoresis (SIFE), and urine immunofixation electrophoresis (UIFE). The κ/λ ratio is considered abnormal when <0.26 or >1.65. If the ratio is normal and both SIFE and UIFE are negative, AL amyloidosis can be excluded with a negative predictive value of 99%. Importantly, bone scintigraphy may be ordered concurrently if the pretest probability for transthyretin (ATTR) amyloidosis is high, but the results of scintigraphy and the monoclonal screen must be interpreted in tandem to avoid misclassification. When light-chain studies are negative and ATTR amyloidosis remains likely, technetium-labeled bone–avid radiotracer scintigraphy is recommended. The preferred protocol uses technetium pyrophosphate (Tc-PYP) with acquisition of both planar and SPECT or SPECT-CT images at 1 or 3 hours post-injection. A myocardial uptake grade of 2 or 3 confirms ATTR amyloidosis in the appropriate clinical context, whereas absent uptake makes cardiac amyloidosis unlikely. Following a positive scintigraphic study, genetic testing of the transthyretin gene is indicated to differentiate wild-type (ATTRwt) from variant (ATTRv) disease and to inform familial counseling.

If monoclonal assays are positive at the outset, prompt hematology consultation is warranted. Tissue confirmation—via Congo red staining demonstrating apple-green birefringence under polarized light and/or amyloid typing by mass spectrometry—establishes AL amyloidosis and guides clone-directed therapy. Regardless of pathway, the overarching objective is early, accurate typing of amyloid, as therapeutic strategies diverge sharply between AL and ATTR. Despite growing awareness, cardiac amyloidosis remains underrecognized. Its protean systemic features and the overlap of cardiac manifestations with prevalent conditions (eg, hypertensive heart disease, hypertrophic cardiomyopathy, and HFpEF) contribute to diagnostic delay. Nevertheless, the disease frequently stamps a recognizable signature across cardiovascular testing, enabling earlier detection when clinicians are primed to look.

Electrocardiography

A standard 12-lead ECG in cardiac amyloidosis may mimic ischemic injury despite unobstructed epicardial coronaries. Typical findings include low limb-lead voltages and pseudo-infarction

Q waves in the anterior and inferior leads (see Image. Cardiac Amyloidosis on Electrocardiography). Conduction system disease is common, with first-degree atrioventricular block representing the most frequent abnormality. These ECG features are particularly characteristic of amyloid light-chain amyloidosis. By contrast, patients with ATTR amyloidosis more often demonstrate left bundle branch block, higher-grade atrioventricular block, and limb-lead voltages that are often maintained, alongside nonspecific ST-T abnormalities. Atrial fibrillation is prevalent across phenotypes and may be the presenting arrhythmia in many patients.[12]

Echocardiography

Echocardiography is often the initial imaging modality to raise suspicion and remains central to screening and diagnosis. A cardinal observation is increased LV wall thickness with a "sparkling" or granular myocardial texture on two-dimensional imaging (see Image. Cardiac Amyloidosis on Transthoracic Echocardiogram).[13] Biatrial enlargement is nearly universal. The LV cavity is typically nondilated; ejection fraction is often preserved early and declines only with advancing infiltration, whereas diastolic dysfunction is present from the outset and tends to progress swiftly. Small pericardial and pleural effusions are common adjunctive findings. Strain imaging substantially augments diagnostic specificity. Global longitudinal strain (GLS) analysis reveals progressive reduction in longitudinal shortening from base to apex, with relative preservation of apical strain that produces the classic "cherry on top" map—considered pathognomonic for cardiac amyloidosis in the appropriate context (see Image. Global Longitudinal Strain Analysis for Cardiac Amyloidosis). An apical-to-basal strain ratio >1.1 is highly sensitive and specific for the condition and can be invaluable when conventional echocardiographic markers are equivocal.[14] Clinical constellations that should further concentrate suspicion include syncope or presyncope, angina in the absence of obstructive coronary disease, heart failure symptoms, discordance between ECG voltages and LV mass, LV hypertrophy with a conspicuously hyperechoic ("bright") myocardium, and the archetypal apical-sparing strain pattern.

Subphenotypic distinctions between AL and ATTR can sometimes be appreciated on echocardiography. In AL amyloidosis, LV wall thickening is more often symmetric, reflecting diffuse interstitial deposition. In ATTR, particularly ATTRwt and many ATTRv variants, asymmetric hypertrophy is comparatively common and may include a sigmoid septal contour. Moreover, ATTR tends to drive a greater deterioration in both systolic and diastolic function over time and is associated with larger increments in left and right ventricular masses than those typically encountered in AL disease.[15] While these patterns are not absolute and cannot substitute for definitive typing, their recognition can refine pretest probability and guide the sequencing of confirmatory tests. In sum, a rigorous, stepwise evaluation—anchored in a high index of suspicion, attentive to systemic markers, and disciplined in test interpretation—enables timely and accurate diagnosis of cardiac amyloidosis. Excluding AL with serum and urine monoclonal studies, confirming ATTR with bone scintigraphy when appropriate, and using echocardiography, ECG, CMR, and biomarkers to construct a coherent picture are the pillars of contemporary practice. Early identification is essential, as therapeutic options are most effective when instituted before advanced structural remodeling and irreversible organ damage have occurred.[12][13][14][15]

Cardiac Magnetic Resonance Imaging

Cardiac magnetic resonance (CMR) imaging has emerged as a cornerstone modality for evaluating suspected cardiac amyloidosis, chiefly because it couples high-fidelity anatomic assessment with robust tissue characterization. In patients with otherwise unexplained myocardial wall thickening, CMR can help discriminate against amyloid infiltration from alternative etiologies such as hypertensive heart disease or cardiac sarcoidosis by revealing patterns of signal behavior that reflect extracellular matrix expansion rather than true myocyte hypertrophy. Equally important, CMR sensitively detects early myocardial involvement—before overt systolic dysfunction—by quantifying diffuse interstitial abnormalities. Notwithstanding these strengths, CMR cannot by itself resolve amyloid type; specifically, it is not able to distinguish transthyretin (ATTR) amyloidosis from amyloid light-chain (AL) disease, thereby necessitating integration with serologic testing and, when indicated, nuclear scintigraphy or tissue typing. The morphologic phenotype of amyloid cardiomyopathy on CMR aligns closely with a restrictive physiology: the ventricles exhibit increased wall thickness with relatively small cavity size, impaired diastolic filling, and disproportionate enlargement of both atria—a reflection of chronically elevated filling pressures. Myocardial mass is typically increased, and segmental systolic thickening may be attenuated in the most infiltrated regions. Late gadolinium enhancement (LGE) imaging furnishes the signature appearance: diffuse, circumferential subendocardial enhancement that transcends coronary territories and, as the burden of deposition intensifies, may progress to transmural involvement. This global, nonischemic distribution contrasts with the subendocardial or transmural patterns circumscribed to vascular distributions in infarction, enabling confident differentiation from ischemic scar in the appropriate clinical context.

Parametric mapping further strengthens diagnostic confidence. Native T1 values are elevated due to the expansion of the interstitial compartment, and extracellular volume (ECV) fraction is increased concordantly, both reflecting the accumulation of insoluble amyloid fibrils within the myocardium.[16] Unlike inflammatory cardiomyopathies, myocardial edema is generally not a prominent feature in amyloidosis, a distinction that can aid differential diagnosis when T2-weighted or T2 mapping sequences are reviewed. Gadolinium kinetics are also distinctive: contrast agent clears rapidly from the left ventricular blood pool while being retained in the amyloid-laden myocardium, a behavior that underlies characteristic inversion-recovery findings. A particularly specific observation is the inversion time (TI) “nulling” phenomenon. In normal hearts, the blood pool nulls at a shorter TI than the myocardium; in cardiac amyloidosis this relationship reverses, with the myocardium nulling before the blood pool. Difficulty in achieving uniform myocardial nulling—or the need for unusually short TIs to null the myocardium—should therefore heighten suspicion for amyloid infiltration.[17] Collectively, these CMR features—restrictive morphology, diffuse nonischemic LGE, elevated native T1 and ECV, and reversed nulling order—provide a cohesive, noninvasive portrait of amyloid cardiomyopathy, even though definitive typing requires complementary tests.

Nuclear Single Photon Emission Computed Tomography

Bone-avid radiotracer scintigraphy interpreted alongside clinical and laboratory data offers a powerful, noninvasive pathway to diagnosing ATTR cardiac amyloidosis. When planar and SPECT (or SPECT-CT) imaging demonstrate cardiac uptake that equals or exceeds skeletal rib activity—classically graded as 2 or 3—or when the quantitative heart-to-chest wall ratio exceeds 1.5 at 1 hour, and echocardiographic features support an infiltrative phenotype in the absence of signs suggestive of multiple myeloma, the constellation is considered nearly diagnostic of ATTR amyloidosis.[18] In contrast, patients with AL amyloidosis typically show minimal or absent myocardial uptake with these bone tracers, underscoring the complementary role of scintigraphy to serologic screening for monoclonal proteins. A widely adopted semiquantitative visual grading scheme compares myocardial radiotracer activity to the ribs:

- **Grade 0:** No myocardial uptake (normal)
- **Grade 1:** Myocardial uptake less than bone (mild)
- **Grade 2:** Myocardial uptake equal to bone (moderate)
- **Grade 3:** Myocardial uptake greater than bone (severe)

In clinical practice, a **grade 2 or 3** uptake, **in the absence of detectable monoclonal proteins**, confirms ATTR cardiac amyloidosis with high specificity. This algorithm simultaneously reduces the need for endomyocardial biopsy in many patients while ensuring that individuals with positive monoclonal screens are evaluated for AL disease, which demands urgent, clone-directed therapy.[18] As such, nuclear scintigraphy occupies a central position in modern diagnostic pathways, particularly for older adults with otherwise unexplained wall thickening, heart failure with preserved ejection fraction, or classical echocardiographic strain patterns.

Endomyocardial Biopsy

Despite advances in imaging, endomyocardial biopsy (EMB) remains the definitive diagnostic standard in cardiac amyloidosis and retains a crucial role when noninvasive findings are discordant, when monoclonal proteins are present, or when precise amyloid typing is required to guide treatment. Histopathologic examination of EMB specimens stained with Congo red reveals the characteristic salmon-pink deposits that, under polarized light, display apple-green birefringence—a pathognomonic optical signature of amyloid fibrils. Beyond confirming the presence of amyloid, contemporary laboratories increasingly rely on mass spectrometry–based proteomic typing to identify the fibril precursor protein with high accuracy, thereby distinguishing AL from ATTR and rarer forms. Although invasive, EMB is highly sensitive for cardiac involvement, with reported sensitivities spanning **87% to 98%**, particularly when multiple right ventricular septal samples are obtained.[19] The procedural risk is low in experienced hands, and the diagnostic yield—especially when integrated with light chain assays and scintigraphy—can be decisive for management.

Genotyping

Genetic testing is integral to the evaluation of patients with confirmed or strongly suspected ATTR amyloidosis. More than 120 pathogenic or likely pathogenic variants in the TTR gene have been associated with cardiac amyloidosis, and the specific genotype exerts a meaningful influence on phenotype, natural history, and therapeutic response.[20] Among the most frequently encountered variants are Thr60Ala and Val122Ile; the former is classically linked with mixed cardiac and neuropathic manifestations in certain geographic clusters, while the latter is strongly associated with late-onset cardiomyopathy and is more prevalent in individuals of West African ancestry. Determining the genotype informs prognosis (e.g., propensity for conduction disease or autonomic involvement), calibrates family counseling and cascade testing, and may shape expectations for responsiveness to transthyretin-stabilizing or gene-silencing therapies. Importantly, variant prevalence is geographically and ethnically patterned, such that awareness of local founder mutations can streamline clinical suspicion and testing strategies.[20] In summary, a comprehensive diagnostic paradigm for cardiac amyloidosis integrates the complementary strengths of CMR, nuclear scintigraphy, histopathology, and genetics. CMR excels at defining the extent and pattern of myocardial involvement and at detecting early, diffuse interstitial disease through LGE and parametric mapping, albeit without amyloid typing capability.[16][17] Bone tracer scintigraphy, when interpreted in tandem with monoclonal protein studies, enables noninvasive confirmation of ATTR in many patients and helps triage those who require tissue diagnosis for AL exclusion.[18] Endomyocardial biopsy provides definitive histologic and proteomic confirmation when necessary, with high sensitivity and specificity, while genotyping crystallizes the ATTR subtype, refines prognosis, and guides familial screening.[19][20] Leveraging these tools within a structured algorithm allows clinicians to move efficiently from suspicion to precise diagnosis, thereby expediting disease-specific therapy at stages when intervention can most effectively alter the trajectory of cardiac dysfunction

Table 1. Diagnostic Modalities and Signature Findings in Cardiac Amyloidosis

Modality	Signature findings	Differentiates from	Limitations	Clinical pearl
12-lead ECG	Low limb-lead voltages; pseudo-infarct Q waves; AV block/AF common	Hypertensive LVH (typically high voltages)	Low sensitivity alone	Voltage–mass discordance strongly suggests infiltrative disease
Echocardiography (GLS)	Increased wall thickness, biatrial enlargement; small pericardial effusion; **apical-sparing** longitudinal strain (“cherry on top”)	HCM (often asymmetric hypertrophy without apical sparing)	Not amyloid-type specific	Apical-to-basal strain ratio >1.1 supports diagnosis
Cardiac MRI (LGE, T1/ECV)	Diffuse subendocardial → transmural LGE; elevated native T1/ECV; **reversed nulling** (myocardium before blood)	Ischemic scar (coronary-territory LGE); sarcoid (patchy mid-wall/subepicardial)	Cannot distinguish ATTR vs AL	Difficulty uniformly nulling myocardium is highly suggestive
Tc-PYP SPECT/CT	Grade 2–3 myocardial uptake; H/Chest-wall ratio >1.5 at 1 h	AL (minimal uptake)	False positives with blood-pool artifact; must pair with monoclonal screen	Grade 2–3 uptake **plus** negative monoclonal studies = ATTR diagnosis
Endomyocardial biopsy	Congo red positive with apple-green birefringence; mass-spec typing	Non-amyloid infiltrative disease	Invasive; sampling error	Gold standard when noninvasive tests are discordant
Genotyping (TTR)	Identifies ATTRv (e.g., Val122Ile, Thr60Ala)	ATTRwt	None for typing; access varies	Guides prognosis, cascade testing, therapy expectations

Table 2. Phenotype-Directed Therapy and Monitoring

Domain	AL (light-chain)	ATTR (wild-type & variant)	Universal/supportive
Primary goal	Rapid eradication of monoclonal light chains	Stabilize/diminish TTR amyloidogenesis	Relieve congestion; prevent thromboembolism
First-line disease-modifying therapy	Dara-CyBorD (daratumumab + cyclophosphamide + bortezomib + dexamethasone); high-dose melphalan + ASCT (eligible)	Tafamidis (cardiomyopathy); TTR silencers (patisiran/inotersen/vutrisiran) for neuropathy	Loop diuretics ± MRA; cautious SGLT2i; midodrine for orthostasis
Advanced options	Heart transplant followed by chemotherapy (selected)	Heart transplant (selected ATTRwt/ATTRv) ± evolving criteria	CRT for AV block (prefer biventricular over RV pacing alone)
Drugs to use cautiously	β-blockers, RAAS inhibitors (hypotension); **digoxin** (fibril binding/toxicity)	β-blockers, non-DHP CCBs (hypotension)	Tailored anticoagulation; avoid over-diuresis (renal injury)
Response monitoring	NT-proBNP/TnT; difference in free light chains; symptoms	NT-proBNP/TnT; functional class; imaging strain/T1/ECV	Weights, orthostatics, renal/electrolytes; readmission rate

Treatment / Management

The therapeutic strategy for cardiac amyloidosis must be individualized and multidimensional, reflecting the interdependence of congestive physiology, arrhythmic burden, and the underlying amyloid biology. Optimal care weaves together meticulous volume control, disease-modifying interventions tailored to amyloid type, and judicious management of heart rate and rhythm. Because medication tolerance is idiosyncratically limited in this population—owing to autonomic dysfunction, fixed stroke volume, and low blood pressure—close titration and frequent reassessment are essential to improve symptoms, preserve functional status, and extend survival.

Heart Failure and Volume Management

Rigorous control of congestion is the foundation of symptomatic therapy. In amyloid light-chain (AL) amyloidosis, loop diuretics are the principal agents for achieving euvolemia, often in combination with a mineralocorticoid receptor antagonist for synergistic natriuresis. By contrast, agents that target the renin–angiotensin–aldosterone system are frequently poorly tolerated in AL disease: even minimal doses can provoke pronounced hypotension because stroke volume is relatively fixed and systemic vascular resistance may already be low. Patients with transthyretin (ATTR) amyloidosis, however, sometimes demonstrate better tolerance of these neurohormonal modulators, though interindividual variability remains considerable and mandates cautious up-titration. Orthostatic hypotension is common, particularly when autonomic failure coexists, and it complicates attempts to relieve fluid overload. In such circumstances, peripheral vasoconstrictors (e.g., midodrine) can be employed strategically to support arterial pressure, enabling the continuation of diuretic therapy without provoking syncope. Nonpharmacologic measures—compression garments, slow positional changes, and liberalization of salt within the constraints of congestion—may confer additional stability [19][20].

β-blockers often precipitate symptomatic hypotension or low-output symptoms, even at very low doses, because heart rate reduction can critically diminish cardiac output in the context of restrictive filling. The development of profound hypotension shortly after β-blocker initiation should heighten suspicion for an underlying infiltrative process such as amyloidosis. For many patients, therefore, loop diuretics and mineralocorticoid receptor antagonists remain the cornerstone agents for heart failure management, with other neurohormonal therapies reserved for carefully selected individuals who demonstrate tolerance. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors may offer incremental benefits in edema control and cardiorenal interactions in selected cases, but amyloid-specific data remain limited. When sequential nephron blockade is required, thiazide-type diuretics (e.g., metolazone) should be deployed sparingly and with vigilant monitoring to avoid overshooting into prerenal azotemia, hypokalemia, or hyponatremia—complications that can destabilize these physiologically fragile patients. Advanced therapies must be considered in the appropriate clinical context. Heart transplantation can be an option for rigorously selected individuals. In AL amyloidosis, isolated orthotopic heart transplantation carries a substantial risk of post-transplant recurrence within the graft because the systemic amyloidogenic stimulus persists. Nevertheless, a strategy of transplantation followed by intensive chemotherapeutic eradication of the plasma-cell clone may be viable in those with clinically predominant cardiac involvement who are prepared for aggressive post-operative therapy; in this scenario, five-year survival rates approaching 60% have been reported. The rationale is pragmatic: the native, amyloid-infiltrated heart often cannot tolerate the hemodynamic stress of high-dose chemotherapy, whereas a new graft provides the reserve needed to complete definitive hematologic treatment [19][20]. Patients with ATTR wild-type (ATTRwt) commonly have disease confined to the heart and, in principle, may be suitable transplant candidates; however, the typical presentation in the seventh decade or later frequently limits eligibility on the basis of age and comorbidity. For individuals with end-stage heart failure who are not candidates for transplantation (or mechanical support), early integration of palliative care is pivotal to aligning treatment with patient priorities, optimizing symptom control, and support caregivers.

Disease-Modifying Therapy

For ATTR amyloid cardiomyopathy—whether hereditary (ATTRv) or wild-type—tafamidis is the only oral therapy currently approved by the U.S. Food and Drug Administration. Tafamidis stabilizes the native transthyretin tetramer, preventing its dissociation into amyloid-prone monomers and oligomers—the initiating step in fibrillogenesis. In the pivotal Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced all-cause mortality and cardiovascular hospitalizations over 30 months compared with placebo, with benefits observed across key prespecified subgroups, including both ATTRv and ATTRwt and New York Heart Association functional classes I–III.[21] Subsequent post hoc analyses suggested attenuation of the progressive decline in left ventricular systolic and diastolic performance, consistent with a cardioprotective effect that moderates disease tempo.[22] The FDA-approved regimens for cardiomyopathy are tafamidis 61 mg or tafamidis meglumine 80 mg daily. Despite clear efficacy, real-world uptake is constrained by cost, which remains a major barrier to access in many health systems.

For patients with ATTRv accompanied by polyneuropathy, transthyretin "silencer" therapies—patisiran, inotersen, and vutrisiran—are available.[23] These agents reduce hepatic TTR synthesis at the mRNA level, thereby lowering circulating transthyretin (mutant and, variably, wild-type) and limiting further amyloid deposition. Because neurologic manifestations drive disability in many ATTRv genotypes, management often requires coordinated co-care with neurology to balance cardiac and neurologic treatment goals, monitor off-target effects, and time interventions appropriately. In AL cardiac amyloidosis, disease control hinges on rapid and deep hematologic responses. Multidisciplinary collaboration between hematology and cardiology is indispensable. The central objective is eradication of circulating monoclonal light chains and suppression of the plasma-cell clone within the marrow. Therapeutic backbones include the alkylator melphalan and the proteasome inhibitor bortezomib, the latter commonly combined with dexamethasone and cyclophosphamide to enhance depth of response. A favorable cardiac response is typically defined by a ≥30% reduction in B-type natriuretic peptide over approximately six months, recognizing that biomarker trajectories often lag behind hematologic responses [22]. For transplant-eligible patients, high-dose melphalan followed by autologous stem cell transplantation (ASCT) remains a standard approach, aiming for rapid, durable clonal control. In those who are not candidates for ASCT due to age, frailty, or multiorgan involvement, the preferred first-line regimen is Dara-CyBorD: daratumumab (a CD38 monoclonal antibody) combined with cyclophosphamide, bortezomib, and dexamethasone. This quadruplet can achieve deep hematologic remissions and, in turn, better cardiac biomarker improvements by sharply curtailing light-chain production at its source [22].

Practical Considerations Across Modalities

Across amyloid phenotypes, medication choices must be continually reconciled with blood pressure tolerance, renal function, and electrolyte balance. Small changes in intravascular volume can precipitate large swings in symptoms due to the noncompliant, infiltrated ventricle; thus, patient education about daily weights, dietary sodium vigilance, and early reporting of edema or presyncope is crucial. Because arrhythmias are prevalent and anticoagulation decisions can be complex—particularly in the setting of autonomic hypotension and fluctuating renal function—shared decision-making and periodic reassessment are recommended. Device therapy (e.g., pacemakers for conduction disease) may be necessary in selected individuals, but the general intolerance of β-blockers and vasodilators often constrains rate-control strategies, reinforcing the primacy of volume optimization.

Integrating Care

Ultimately, management is most effective when embedded in an interprofessional framework that links cardiology, hematology, neurology, transplant services, pharmacy, palliative care, and specialized nursing. For AL disease, the speed and depth of hematologic response dictate cardiac outcomes; for ATTR, timely initiation of transthyretin-directed therapy can slow progression and improve event-free survival. In all cases, vigilant volume management, thoughtful mitigation of orthostatic symptoms (e.g., with midodrine), and avoidance of poorly tolerated agents (notably β-blockers in many patients) form the daily scaffolding of care. As therapeutic options expand, early recognition and precise amyloid typing remain the decisive steps that unlock disease-specific therapy and, with it, the best opportunity to alter the trajectory of this otherwise relentlessly progressive cardiomyopathy.[21][22][23]

Management of Arrhythmias

Arrhythmia care in cardiac amyloidosis demands a tailored strategy that balances symptom relief, prevention of thromboembolism, and the unique hemodynamic vulnerabilities imposed by an infiltrative, stiff myocardium. Depending on the rhythm disturbance, patients may require rate or rhythm control and, particularly in atrial fibrillation, systematic anticoagulation to mitigate embolic risk. Device therapy is frequently necessary in selected contexts—permanent pacing for conduction disease and implantable cardioverter-defibrillators for secondary prevention after malignant ventricular arrhythmias or aborted sudden cardiac death. Atrial arrhythmias pose a distinctive therapeutic challenge. Conventional rate-controlling agents such as β-blockers are often poorly tolerated because even modest reductions in heart rate can precipitate symptomatic hypotension in the setting of fixed stroke volume and autonomic dysfunction. Indeed, the development of profound hypotension after initiation of low-dose β-blockade should prompt consideration of underlying amyloid cardiomyopathy. In this population, amiodarone is a reasonable alternative with generally acceptable tolerability and efficacy for both rate and rhythm control. While amiodarone's extracardiac toxicities mandate surveillance, its hemodynamic neutrality makes it particularly suitable for patients in whom hypotension constrains other options [21][22][23].

Digoxin requires special caution. The drug can bind to amyloid fibrils, potentially increasing tissue levels and predispose to toxicity. Nevertheless, with meticulous dosing, careful monitoring of renal function and serum concentrations, and vigilance for early signs of digoxin effect, it may be employed for rate control in selected patients with atrial fibrillation who cannot tolerate alternatives. Non-dihydropyridine calcium channel blockers have not demonstrated meaningful benefit in amyloid-related diastolic dysfunction and may exacerbate hypotension; as such, they are generally avoided. Overall, rate/rhythm strategies must be individualized, with frequent reassessment for blood pressure tolerance, organ perfusion, and symptom relief. Catheter ablation has a circumscribed role. For typical atrial flutter, ablation may be attempted and can be useful in reducing symptomatic burden. In contrast, atrial fibrillation associated with amyloidosis carries a high recurrence rate after ablation because of extensive atrial remodeling and ongoing substrate progression; thus, expectations should be tempered, and ablation decisions should incorporate overall frailty, procedural risk, and patient goals. Crucially, anticoagulation is often indicated irrespective of rhythm status or apparent symptom severity. Atrial amyloid infiltration and impaired atrial mechanical function heighten the risk of intracardiac thrombus and systemic thromboembolism; therefore, anticoagulation decisions lean strongly toward treatment unless contraindications predominate [21][22][23].

Diseases conduction systems is common and frequently progressive. In patients with atrioventricular block, biventricular pacing (cardiac resynchronization therapy) is preferred over isolated right ventricular pacing. Right ventricular pacing can exacerbate dyssynchrony and depress cardiac performance in a noncompliant, amyloid-infiltrated ventricle, whereas biventricular pacing better preserves coordinated contraction and hemodynamics. For ventricular arrhythmias, implantable cardioverter-defibrillators for *primary* prevention have not demonstrated a survival advantage in this disease context and are generally not recommended. Their use is reserved for *secondary* prevention in individuals who have experienced documented life-threatening ventricular tachyarrhythmias or an aborted sudden death, where protection from recurrent malignant rhythms is clearly warranted [21][22][23].

Liver Transplantation

Orthotopic liver transplantation occupies a defined, though specialized, niche in the management of hereditary transthyretin (ATTRv) amyloidosis. Because the liver is the principal source of circulating transthyretin, replacing the native organ halts production of the mutant protein and, by doing so, can curb further deposition of variant TTR. This disease-modifying logic does not apply to wild-type transthyretin (ATTRwt) or to amyloid light-chain amyloidosis, and liver transplantation is not generally pursued in those settings. Historically, combined consideration of liver transplantation has been strongest for ATTRv patients at risk for or manifesting neuropathy. In such individuals, a heart transplant alone may inadvertently accelerate neuropathic progression if the mutant TTR source remains intact, whereas liver replacement removes the driver of ongoing neural and cardiac deposition. The advent of transthyretin "silencing" therapeutics and stabilizers has complicated the calculus, creating new, less invasive pathways to suppress mutant protein production. Consequently, contemporary criteria for isolated liver transplantation or combined heart-liver transplantation are evolving, and the optimal timing and selection thresholds remain areas of active investigation. Multidisciplinary evaluation—integrating cardiology, neurology, hepatology, and transplant surgery—is essential to weigh the benefits of halting mutant TTR synthesis against operative risks, comorbidity, and the availability and efficacy of pharmacologic alternatives [21][22][23]

Palliative Care

Palliative care is integral to comprehensive amyloidosis management and should be introduced early, not only in the terminal phase. The symptom constellation—fatigue, dyspnea, edema, orthostatic intolerance, neuropathic pain, gastrointestinal dysmotility, and anxiety—exacts a substantial toll on function and quality of life. Proactive palliative engagement focuses on clarifying goals of care, aligning treatment intensity with patient values, and implementing targeted symptom control to enable the fullest possible participation in daily activities. Key components include meticulous relief of distressing symptoms (e.g., edema control, breathlessness strategies, and neuropathic pain management), psychological and spiritual support that acknowledges the uncertainty and chronicity of the illness, and communication frameworks that normalize discussions about prognosis and preferences. Because cardiac amyloidosis often progresses despite best efforts, palliative teams also help patients and families anticipate transitions—such as the need for assistive devices, home supports, or hospice—and navigate complex choices about hospitalization versus home-based care. Importantly, affirming life while recognizing death as a natural process allows patients and clinicians to prioritize comfort, dignity, and relationships without abandoning disease-directed therapy when it remains aligned with patient aims. Family and caregiver support is a cornerstone. The burdens of frequent appointments, dietary restrictions, medication adjustments, and the vigilance required to manage orthostatic symptoms or arrhythmia triggers can be substantial. Palliative care provides education, respite resources, and coping strategies for caregivers, reducing burnout and enhancing the sustainability of home management. In advanced stages, particularly for individuals ineligible for transplantation or lacking further disease-modifying options—palliative teams coordinate with cardiology to fine-tune diuretic regimens, deprescribe poorly tolerated agents, and establish clear plans for symptom crises, including how to respond to recurrent ICD shocks when devices are present for secondary prevention [21][22][23].

In sum, arrhythmia management in cardiac amyloidosis centers on cautious, individualized rate and rhythm strategies, liberal use of anticoagulation given the high thromboembolic propensity, and judicious deployment of pacing and defibrillation with an emphasis on biventricular support for conduction disease and secondary prevention for malignant ventricular rhythms. Liver transplantation retains a selective role for ATTRv by eliminating the hepatic source of mutant transthyretin, though its indications continue to evolve in the era of gene-silencing therapies. Throughout the disease course, early and ongoing palliative care—anchored in symptom relief, psychosocial and spiritual support, and comprehensive family engagement—enhances quality of life and ensures that treatment remains consonant with each patient's values and goals.

Differential Diagnosis

Because cardiac amyloidosis produces a restrictive filling pattern with relatively normal—or only modestly reduced—left ventricular ejection fraction, it can be mistaken for any disorder that yields a similar hemodynamic profile. The overlap is most conspicuous in dyspnea that persists despite preserved ejection fraction, progressive diastolic dysfunction, and biatrial enlargement, all of which appear across the restrictive cardiomyopathy spectrum. Among the most consequential mimics are cardiac sarcoidosis, glycogen storage disorders, and hemochromatosis. Hypertensive heart disease and hypertrophic cardiomyopathy (HCM) also confound the picture owing to shared echocardiographic signs, especially increased wall thickness. Distinguishing amyloidosis from cardiac sarcoidosis hinges on recognizing granulomatous inflammation rather than protein deposition. Sarcoidosis often features conduction block and ventricular arrhythmias, as amyloidosis does, but advanced imaging patterns diverge late gadolinium enhancement (LGE) in sarcoidosis tends to be patchy, mid-myocardial or subepicardial, and frequently basal septal, whereas amyloid classically shows diffuse subendocardial or transmural enhancement with difficulty uniformly nulling the myocardium. Fluorodeoxyglucose positron emission tomography (FDG-PET) commonly reveals focal inflammatory uptake in sarcoidosis; a finding not expected in amyloid infiltration. Moreover, extracardiac sarcoid involvement—pulmonary or lymphatic—can provide decisive diagnostic leverage [24].

Glycogen storage cardiomyopathies (e.g., PRKAG2-related disease or Danon disease) may present with concentric thickening, conduction disease, and pre-excitation on ECG. Unlike amyloidosis, however, these disorders typically emerge at younger ages, may demonstrate very high voltages on ECG (rather than voltage-mass discordance), and are accompanied by skeletal myopathy or characteristic metabolic markers. Endomyocardial biopsy, when pursued, reveals vacuolated myocytes with glycogen accumulation, not Congo red–positive material. Systemic iron overload in hemochromatosis can also mimic amyloidosis by producing restrictive physiology and arrhythmias. Yet T2* cardiac magnetic resonance sequences are uniquely sensitive to myocardial iron deposition, and iron indices (serum ferritin and transferrin saturation) support the diagnosis. As with amyloidosis, conduction system involvement and heart failure are common; nevertheless, the ability to reverse or ameliorate iron-mediated toxicity with phlebotomy or chelation underscores the importance of accurate differentiation. Hypertensive heart disease and HCM are ubiquitous sources of diagnostic confusion. Hypertension induces true myocyte hypertrophy with increased voltages on ECG, while amyloid typically causes "voltage-to-mass" discordance (low voltages despite thick walls) and a granular sparkling texture on echocardiography. In HCM, wall thickening is often asymmetric (particularly in the interventricular septum), with dynamic left ventricular outflow tract obstruction in many patients; longitudinal strain does not usually show the distinctive apical-sparing pattern that is highly suggestive of amyloidosis. When uncertainty persists, tissue characterization with cardiac MRI, serum/urine monoclonal protein studies, bone-avid tracer scintigraphy (for transthyretin amyloidosis), and, when necessary, endomyocardial biopsy resolve the differential. In practice, a systematic approach that integrates clinical context (age, extracardiac red flags such as carpal tunnel syndrome or autonomic dysfunction), ECG–echo discordance, strain imaging, and targeted laboratory testing prevents misclassification and expedites definitive diagnosis [24].

Prognosis

Outcomes in cardiac amyloidosis vary markedly by amyloid type and disease stage. In the absence of treatment, amyloid light-chain (AL) cardiac amyloidosis carries the gravest outlook, with median survival on the order of 6 to 12 months. In transthyretin-derived disease, survival is longer but still limited: wild-type transthyretin (ATTRwt) cardiomyopathy typically exhibits median survival of 3.6 to 4.8 years, whereas the hereditary form (ATTRv) is heterogeneous. For ATTRv associated with the Val122Ile substitution, median survival is approximately 2.6 years; for other transthyretin mutations, median survival extends to roughly 5.8 years. Overall, ATTR amyloidosis tends to progress more slowly than AL disease and generally presents later in life, most commonly in the seventh decade, contributing to a comparatively better prognosis in aggregate. Therapeutic advances have substantially altered trajectories in selected subgroups. In AL amyloidosis, deep hematologic responses translate into improved cardiac outcomes, particularly when autologous stem cell transplantation (SCT) is feasible. Among patients with AL who undergo SCT, four-year survival exceeds 90%. In those with cardiac involvement who receive a heart transplant, median survival may surpass 10 years, especially when post-transplant hematologic therapy effectively suppresses the plasma cell clone. In the broader AL population, median survival approaches a decade with contemporary regimens, though advanced-stage disease remains perilous, with one-year survival falling to roughly 50% [24].

For mutant ATTR amyloidosis, four-year survival has been reported at approximately 16%, underscoring the impact of genotype on prognosis.

The Val30Met mutation, the most common worldwide—is associated with an overall survival of 79%, whereas the Val122Ile variant portends a less favorable four-year prognosis of about 40%.[24] These figures highlight not only the heterogeneity of ATTRv but also the need to integrate genotype into counseling, therapeutic selection, and family screening. Across amyloid types, several clinical and biomarker features stratify risk. Adverse prognostic markers include elevated cardiac troponin I and NT-proBNP, left ventricular wall thickness greater than 15 mm, advanced stages of diastolic dysfunction, multisystem involvement (e.g., renal, hepatic, or neurologic), and the presence of atrial or ventricular arrhythmias. These elements inform established staging schemas that guide expectations and management intensity. For AL amyloidosis, the widely used Mayo Clinic staging system employs three thresholds: NT-proBNP > 1,800 pg/mL, troponin T > 0.025 ng/mL, and a difference in serum free light chains (involved minus uninvolved) > 18 mg/dL. Stage I (all below threshold) is associated with a median survival of roughly five years; Stage II (one marker above threshold) carries a median survival near 3.5 years; Stage III (two markers elevated) corresponds to a median survival of about 1.5 years; and Stage IV (all three elevated) portends a median survival of approximately six months. For ATTR amyloidosis, staging hinges on NT-proBNP and troponin T: Stage I (NT-proBNP ≤ 3,000 pg/mL and troponin T ≤ 0.05 ng/mL) corresponds to a median survival of about 5.7 years; Stage II (exceed either threshold) yields a median survival near 4.2 years; and Stage III (both above threshold) is linked to a median survival of roughly 2.5 years.[25] These frameworks provide a shared language for clinicians and patients and help align the aggressiveness of therapy with anticipated benefit [25]. Importantly, prognosis is dynamic: biomarker trends after therapy, changes in functional capacity, and imaging responses (e.g., stabilization of extracellular volume on cardiac MRI or improvement in strain patterns) refine risk over time. Early diagnosis is therefore pivotal; treatment initiated before advanced structural remodeling confers the greatest potential to stabilize or slow disease [25].

Complications

Complications in cardiac amyloidosis arise from the interplay of a stiff, infiltrated ventricle, atrial remodeling, conduction system disease, and multisystem involvement. Atrial fibrillation is exceedingly common and drives a substantial portion of morbidity. Loss of atrial contribution to ventricular filling is particularly detrimental in restrictive physiology, precipitating decompensated heart failure and limiting exercise tolerance. Moreover, atrial amyloid infiltration impairs mechanical function even during sinus rhythm, predisposing to atrial thrombosis. Consequently, thromboembolic events—stroke and systemic embolism—remain an ever-present risk and often necessitate anticoagulation irrespective of CHA_2DS_2-VASc scores. Diastolic dysfunction is nearly universal and deepens as interstitial deposition advances. Elevated filling pressures lead to pulmonary congestion, peripheral edema, and recurrent hospitalizations, each episode accelerating frailty and organ dysfunction. Over time, systolic function may decline as well, particularly in transthyretin disease, compounding heart failure severity and heightening mortality. Ventricular arrhythmias—including non-sustained and sustained ventricular tachycardia—occur in a subset of patients and, together with bradyarrhythmias from sinus node dysfunction or atrioventricular block, contribute to syncope and sudden cardiac events. Device therapy mitigates risk in carefully selected cases (e.g., biventricular pacing for high-grade block), but implantable defibrillators have not demonstrated clear survival benefit for primary prevention, underscoring the complexity of risk prediction in this population. Conduction abnormalities are a hallmark complication. Progressive infiltration of the atrioventricular node and His–Purkinje system manifests as first-degree block, bundle branch blocks, and, ultimately, high-grade atrioventricular block requiring pacing. In a noncompliant ventricle, right ventricular pacing alone can aggravate dyssynchrony and depress stroke volume; thus, biventricular pacing is often preferred when pacing indications coexist with heart failure [24][25].

Systemic amyloid involvement extends complications beyond the heart. Autonomic neuropathy leads to orthostatic hypotension, gastrointestinal dysmotility (diarrhea, constipation, early satiety), and genitourinary dysfunction, all of which compromise nutrition, medication tolerance, and rehabilitation. Peripheral neuropathy produces pain, sensory loss, and gait instability, raising fall risk. Tendinopathies—classically biceps tendon rupture and carpal tunnel syndrome—impair upper extremity function and quality of life, while spinal stenosis exacerbates mobility limitations. Renal amyloid deposition can drive proteinuria and progressive chronic kidney disease, tightening the therapeutic window for diuretics and anticoagulants and complicating the use of disease-modifying agents. Psychological and social consequences are pervasive. The burden of frequent decompensations, complex medication regimens, and uncertainty about disease trajectory fosters anxiety and depression for patients and caregivers alike. As a result, early engagement of palliative care to address symptom control, coping strategies, and advance care planning meaningfully improves quality of life and should be considered a standard component of comprehensive care. In summary, the differential diagnosis of cardiac amyloidosis spans the gamut of restrictive and hypertrophic heart diseases, demanding a methodical workup that cross-references clinical red flags with multimodality testing. Prognosis hinges on amyloid type, disease stage, and response to therapy; AL disease carries the shortest untreated survival, while ATTR—especially in non-Val122Ile variants—progresses more slowly, though genotype-specific risks remain salient.[24][25] Complications reflect the diffuse cardiac and systemic footprint of amyloid deposition: atrial and ventricular arrhythmias, conduction disease, thromboembolism, relentless diastolic dysfunction with heart failure hospitalizations, autonomic and peripheral neuropathy, and musculoskeletal limitations. Recognizing these patterns is essential both for timely diagnosis and for implementing integrated, goal-concordant management that mitigates risk and preserves function for as long as possible.

Patient Education

Effective patient education in cardiac amyloidosis must be disease-specific, longitudinal, and coordinated across disciplines. Three professional groups—pharmacists, nurses, and radiologists/nuclear medicine physicians—are pivotal to translating complex diagnostics and nuanced therapeutics into safe, comprehensible, and affordable care [25].

Pharmacists occupy a central role in medication literacy and safety. Because patients with cardiac amyloidosis often exhibit marked sensitivity to even minimal doses of vasoactive agents, pharmacists lead individualized counseling on cautious titration, orthostatic symptom recognition, and self-monitoring (e.g., daily weights, blood pressure logs). They clarify why heart-failure regimens diverge from standard guidelines, explaining, for example, why β-blockers or high-dose renin–angiotensin–aldosterone system inhibitors may worsen hypotension, while loop diuretics and mineralocorticoid receptor antagonists remain foundational. For patients with atrial fibrillation, pharmacists educate on anticoagulant indications, adherence strategies, food–drug interactions, and sick-day rules when renal function fluctuates. Critically, they discuss amyloid-specific risks, such as heightened digoxin toxicity due to fibril binding, and advise on symptom triggers that should prompt urgent evaluation. In amyloid light-chain disease, pharmacists help patients understand combination regimens (e.g., bortezomib-based therapy, daratumumab), premedication to mitigate infusion reactions, and schedules for laboratory surveillance. In transthyretin amyloidosis, they counsel on tafamidis adherence and expectations (disease stabilization rather than fast symptom reversal), while explaining gene-silencing agents when neuropathy coexists. Given the substantial financial toxicity of novel agents, pharmacists also spearhead navigation of prior authorizations, appeals, patient-assistance programs, biosocial supports, and co-pay foundations—converting theoretical efficacy into real-world access [25].

Nurses—including advanced practice nurses and nurse educators—are the linchpin of day-to-day self-management coaching. They reinforce practical skills: sodium and fluid restriction tailored to congestion, stepwise diuretic self-adjustment plans agreed upon with prescribers, safe positional changes to mitigate orthostatic hypotension, and use of compression garments. Bedside and clinic nurses teach symptom pattern recognition (progressive dyspnea, edema, early satiety, syncope) and device-related care after pacemaker/CRT-P/ICD implantation. They also coordinate home blood pressure and weight monitoring programs, remote alerts for decompensation, and rapid access pathways that avert avoidable hospitalization. In systemic disease, nurses provide neuropathy education (foot care, gait aids, fall precautions) and bowel regimen planning for autonomic dysfunction. Because follow-up intervals are necessarily shorter in amyloidosis than in other heart-failure syndromes, nursing-led telephone triage and virtual check-ins maintain continuity, reconcile medications across transitions, and detect early adverse effects (renal dysfunction, electrolyte shifts, hypotension) that necessitate prompt dose adjustments [25].

Radiologists and nuclear medicine physicians educate patients about the purpose and meaning of specialized imaging that underpins diagnosis and monitoring. Before cardiac magnetic resonance (CMR), radiologists explain the value of tissue characterization (late gadolinium enhancement, native T1, and extracellular volume mapping) and counsel on contrast safety, especially in individuals with impaired renal function, selecting macrocyclic gadolinium agents and dose-minimizing protocols when appropriate. They prepare patients for breath-holding sequences, address claustrophobia with evidence-based mitigation strategies, and clarify that CMR cannot determine amyloid type—preventing misinterpretation and aligning expectations for subsequent laboratory or nuclear testing. In bone-avid tracer scintigraphy (e.g., technetium pyrophosphate with SPECT/CT), nuclear medicine teams describe the injection, timing, and semiquantitative grading (0–3), and emphasize why parallel testing for monoclonal proteins is essential to avoid misattribution of ATTR in the presence of AL disease. By demystifying the imaging pathway, these specialists improve adherence to diagnostic algorithms and reduce anxiety that can derail care. Across all three disciplines, equity-oriented education is crucial. Pharmacists normalize discussions about affordability, offer cultural and linguistically appropriate materials, and link patients to financial counseling. Nurses screen for social determinants that undermine adherence—transportation barriers, food insecurity, limited caregiver support—and connect patients with community resources. Radiology departments implement patient-friendly scheduling and same-day protocols that reduce travel and time costs, thereby improving completion rates for essential studies [25].

Enhancing Healthcare Team Outcomes

The prognosis of cardiac amyloidosis hinges on early recognition and precise phenotyping; thus, interprofessional collaboration is not ancillary—it is determinative. Pharmacists, nurses, and radiologists drive measurable improvements in timeliness, safety, and patient-centeredness across the continuum.

Pharmacists operationalize guideline-informed, amyloid-specific therapeutics into reliable practice. They build standardized order sets that reflect dose ceilings and stop rules for hypotension, design laboratory monitoring bundles (electrolytes, renal indices, troponin/NT-proBNP cadence), and deploy decision-support alerts for high-risk interactions (e.g., amiodarone with anticoagulants; daratumumab's interference with antibody screening). In AL amyloidosis, pharmacists coordinate chemotherapy delivery with cardiology visits to synchronize diuretic adjustments around infusion days and preempt fluid shifts. They also measure and report medication-related outcome metrics—time-to-tafamidis initiation post-diagnosis, anticoagulant adherence rates, or avoidable emergency visits attributed to hypotension—which inform quality improvement and payer contracts. Nursing leadership translates multidisciplinary plans into consistent, patient-facing workflows. Nurse navigators establish "fast-track amyloid" pathways: standardized triage for red-flag constellations (HFpEF plus carpal tunnel, voltage–mass discordance on ECG/echo), reflex monoclonal protein testing, and coordinated scheduling of CMR and bone scintigraphy. In the inpatient setting, heart-failure nurses implement diuretic protocols that integrate orthostatic vitals and timely electrolyte replacement, reducing readmissions. They also embed palliative care early—goal-setting, advance care planning, and caregiver training—ensuring that supportive measures (neuropathic pain control, bowel regimens, anxiety management) evolve in tandem with disease-modifying therapy. Post-device implantation, nursing-run remote monitoring clinics detect conduction deterioration or inappropriate ICD therapies promptly, avoiding decompensation [25].

Radiologists and nuclear medicine physicians enhance diagnostic yield and shorten time-to-diagnosis through protocol optimization and interpretive expertise. They standardize CMR sequences for suspected amyloidosis (free-breathing motion-corrected mapping when breath-holds are limited; short-TI inversion recovery for difficult myocardial nulling) and align reporting with cardiology decision needs (explicit comment on diffuse subendocardial vs transmural enhancement, native T1/ECV values benchmarked to lab-specific reference ranges). Nuclear medicine teams ensure SPECT/CT acquisition to avoid blood-pool artifacts and include heart-to-contralateral lung or heart-to-chest wall ratios when appropriate, thereby improving reproducibility. Importantly, radiologists close the loop by recommending next steps in reports (e.g., "correlate with serum/urine immunofixation and free light chains"), which nudges downstream testing and reduces diagnostic delay. Together, these disciplines strengthen transitions of care, a notorious failure point in complex cardiomyopathies. Pharmacists lead discharge reconciliation and teach diuretic self-titration algorithms; nurses coordinate early post-discharge contact and symptom reviews; radiology ensures pending studies are scheduled before discharge with clear patient instructions. This choreography curbs readmissions and accelerates initiation of disease-modifying therapy. Finally, the triad contributes to research and learning health systems. Pharmacists maintain registries of tafamidis and gene-silencer outcomes, capturing adherence, discontinuation causes, and cost offsets. Nursing teams collect patient-reported outcomes (fatigue, dyspnea, orthostatic burden), embedding them into routine visits to guide therapy and to evaluate new care models. Radiology curates imaging biobanks with harmonized mapping metrics, enabling phenotypic clustering and response assessment across amyloid subtypes. Feedback from these real-world data streams iteratively refines protocols, improves equity, and elevates the standard of care. In sum, while cardiologists, hematologists, and neurologists direct disease-specific decisions, pharmacists, nurses, and radiologists are the indispensable translators and integrators. Their educational outreach, protocolized monitoring, and imaging stewardship transform a complex, resource-intensive diagnosis into coherent, accessible, and safer care—ultimately improving time-to-diagnosis, treatment adherence, symptom control, and quality of life for patients with cardiac amyloidosis [25].

Conclusion:

Cardiac amyloidosis is no longer a diagnostic rarity but a frequently overlooked cause of heart failure with preserved ejection fraction, conduction disease, and refractory congestion. Outcomes improve when clinicians apply a disciplined algorithm that first excludes AL with serum/urine monoclonal studies, then leverages bone–avid scintigraphy for ATTR confirmation, while CMR defines burden and distribution of myocardial involvement. Therapy must be phenotype-specific: rapid, deep hematologic responses using proteasome-inhibitor–based regimens and, when eligible, autologous transplantation transform prognosis in AL; transthyretin stabilization with tafamidis (and silencers for neuropathy) slows trajectory in ATTR. Across both forms, meticulous volume management and early anticoagulation for atrial disease are foundational, whereas β-blockers and vasodilators require caution. Pharmacists operationalize safety and access—titrating diuretics, monitoring toxicity, resolving prior authorizations for high-cost agents, and educating on adherence and interactions. Nurses orchestrate frequent follow-up, remote monitoring, orthostatic and fall-prevention strategies, device care, and palliative integration that honors patient goals. Radiologists and nuclear medicine physicians standardize CMR and Tc-PYP SPECT/CT protocols, report with actionable language, and close diagnostic loops that expedite definitive typing. This interprofessional choreography converts complex diagnostics and costly therapeutics into equitable, patient-centered care, reducing delays, avoidable admissions, and treatment intolerance while extending quality life years for individuals living with cardiac amyloidosis.

References:

1. Writing Committee. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126.
2. Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10-9.
3. Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy.
4. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018 Apr 01;18(Suppl 2):s30-s35.
5. Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. Int J Cardiol. 2020 Apr 01;304:138-143.
6. Lei C, Zhu X, Hsi DH, Wang J, Zuo L, Ta S, Yang Q, Xu L, Zhao X, Wang Y, Sun S, Liu L. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. BMC Cardiovasc Disord. 2021 Jan 21;21(1):43.
7. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan;28(1):10-21.
8. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171-4.
9. Bajwa F, O'Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev. 2022 Sep;27(5):1471-1484.
10. Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail. 2019 Jun;12(6):e005407.
11. Porcari A, Rossi M, Cappelli F, Canepa M, Musumeci B, Cipriani A, Tini G, Barbati G, Varrà GG, Morelli C, Fumagalli C, Zampieri M, Argirò A, Vianello PF, Sessarego E, Russo D, Sinigiani G, De Michieli L, Di Bella G, Autore C, Perfetto F, Rapezzi C, Sinagra G, Merlo M. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022 Jul;24(7):1227-1236.
12. Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013 Mar;18(2):157-62.
13. Kiotsekoglou A, Saha SK, Nanda NC, Lindqvist P. Echocardiographic diagnosis of cardiac amyloidosis: Does the masquerader require only a "cherry on top"? Echocardiography. 2020 Nov;37(11):1713-1715.
14. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 04;135(14):1357-1377.
15. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, Aimo A, Baggiano A, Martinez-Naharro A, Whelan C, Quarta C, Passino C, Castiglione V, Chubuchnyi V, Spini V, Taddei C, Vergaro G, Petrie A, Ruiz-Guerrero L, Moñivas V, Mingo-Santos S, Mirelis JG, Dominguez F, Gonzalez-Lopez E, Perlini S, Pontone G, Gillmore J, Hawkins PN, Garcia-Pavia P, Emdin M, Fontana M. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020 Apr;13(4):909-920.
16. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18;111(2):122-4.
17. Tipoo Sultan FA, Khan MT. Clinical presentation, diagnostic features on cardiac magnetic resonance imaging and outcome of patients with cardiac amyloidosis presenting to a tertiary care setting. J Pak Med Assoc. 2021 Dec;71(12):2802-2805.
18. Li W, Uppal D, Wang YC, Xu X, Kokkinidis DG, Travin MI, Tauras JM. Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021. Diagnostics (Basel). 2021 May 30;11(6)
19. Bowen K, Shah N, Lewin M. AL-Amyloidosis Presenting with Negative Congo Red Staining in

the Setting of High Clinical Suspicion: A Case Report. Case Rep Nephrol. 2012;2012:593460.

20. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C., THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72.
21. Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 Feb;23(2):277-285.
22. Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ, Maurer MS, Boman K, Gundapaneni B, Sultan MB, Elliott P. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. JAMA Cardiol. 2024 Jan 01;9(1):25-34.
23. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL., American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 07;142(1):e7-e22.
24. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, Emdin M, Rapezzi C. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022 Dec;24(12):2342-2351.
25. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95